Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

OABI

OmniAb Inc

May 03 • 04:00PM ET

4.67

Dollar change +0.07
Percentage change 1.52	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT DFAS DFAC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.51	Insider Own	19.16%	Shs Outstand	116.86M	Perf Week	4.24%
Market Cap	547.00M	Forward P/E	-	EPS next Y	-0.38	Insider Trans	2.25%	Shs Float	94.69M	Perf Month	-12.71%
Income	-50.62M	PEG	-	EPS next Q	-0.16	Inst Own	59.12%	Short Float	5.81%	Perf Quarter	-19.34%
Sales	34.16M	P/S	16.01	EPS this Y	-14.95%	Inst Trans	0.72%	Short Ratio	11.02	Perf Half Y	3.55%
Book/sh	2.69	P/B	1.73	EPS next Y	35.67%	ROA	-12.03%	Short Interest	5.51M	Perf Year	42.38%
Cash/sh	0.74	P/C	6.29	EPS next 5Y	-	ROE	-15.43%	52W Range	3.14 - 6.72	Perf YTD	-24.31%
Dividend Est.	-	P/FCF	781.42	EPS past 5Y	-	ROI	-15.04%	52W High	-30.45%	Beta	-0.05
Dividend TTM	-	Quick Ratio	4.11	Sales past 5Y	13.92%	Gross Margin	44.37%	52W Low	48.73%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	4.11	EPS Y/Y TTM	-121.77%	Oper. Margin	-202.63%	RSI (14)	42.28	Volatility	2.85% 3.09%
Employees	106	Debt/Eq	0.08	Sales Y/Y TTM	-3.34%	Profit Margin	-148.16%	Recom	1.00	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-292.72%	Payout	-	Rel Volume	0.75	Prev Close	4.60
Sales Surprise	-35.38%	EPS Surprise	1.75%	Sales Q/Q	-86.36%	Earnings	May 09 AMC	Avg Volume	499.64K	Price	4.67
SMA20	-3.00%	SMA50	-10.51%	SMA200	-12.03%	Trades		Volume	374,077	Change	1.52%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
08:27AM	Loading…
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
09:00AM	Loading…
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
08:03AM	Loading…
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 08 '24	Sale	5.27	6,954	36,648	176,697	Apr 09 06:38 PM
Berkman Charles S	Chief Legal Officer	Apr 08 '24	Sale	5.27	6,954	36,648	292,617	Apr 09 06:37 PM
GUSTAFSON KURT A	Executive VP, Finance & CFO	Apr 01 '24	Sale	5.46	11,849	64,696	170,110	Apr 02 06:30 PM
FOEHR MATTHEW W	President and CEO	Mar 27 '24	Option Exercise	3.72	243,613	907,023	3,152,416	Mar 29 04:52 PM
FOEHR MATTHEW W	President and CEO	Mar 22 '24	Buy	5.19	225,000	1,167,750	2,908,803	Mar 25 07:07 AM
FOEHR MATTHEW W	Chief Executive Officer	Dec 12 '23	Buy	5.05	200,000	1,010,000	2,645,442	Dec 13 03:25 PM
FOEHR MATTHEW W	President and CEO	Nov 10 '23	Buy	4.27	95,000	405,517	2,427,919	Nov 13 08:00 AM
FOEHR MATTHEW W	President and CEO	Aug 14 '23	Buy	5.48	45,000	246,600	2,332,919	Aug 15 04:56 PM
FOEHR MATTHEW W	Chief Executive Officer	Jun 09 '23	Buy	4.52	115,000	519,800	2,574,009	Jun 12 04:47 PM
HIGGINS JOHN L	Director	May 23 '23	Option Exercise	3.68	9,000	33,120	2,471,686	May 25 04:45 PM
HIGGINS JOHN L	Director	May 23 '23	Sale	4.05	9,000	36,450	2,462,686	May 25 04:45 PM
HIGGINS JOHN L	Director	May 19 '23	Option Exercise	3.68	1,000	3,680	2,463,686	May 23 04:12 PM
HIGGINS JOHN L	Director	May 19 '23	Sale	4.05	1,000	4,050	2,462,686	May 23 04:12 PM
HIGGINS JOHN L	Director	May 18 '23	Option Exercise	3.68	50,000	184,000	2,512,686	May 19 05:03 PM
HIGGINS JOHN L	Director	May 18 '23	Sale	3.89	50,000	194,500	2,462,686	May 19 05:03 PM
FOEHR MATTHEW W	Chief Executive Officer	May 12 '23	Buy	3.40	440,000	1,496,000	2,438,414	May 15 04:02 PM

Open in Screener

LGND

Ligand Pharmaceuticals, Inc.

May 03 • 04:00PM ET

73.90

Dollar change +1.58
Percentage change 2.18	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

LGND Ligand Pharmaceuticals, Inc. daily Stock Chart

Held by: IJR VTI VB IWM VBR VXF IJS PJP IWN IBB

Index	RUT	P/E	25.47	EPS (ttm)	2.90	Insider Own	6.24%	Shs Outstand	17.56M	Perf Week	4.72%
Market Cap	1.33B	Forward P/E	13.19	EPS next Y	5.60	Insider Trans	-0.18%	Shs Float	16.84M	Perf Month	-5.23%
Income	52.15M	PEG	1.27	EPS next Q	0.83	Inst Own	91.74%	Short Float	4.91%	Perf Quarter	-0.86%
Sales	131.31M	P/S	10.11	EPS this Y	-27.09%	Inst Trans	-0.32%	Short Ratio	4.61	Perf Half Y	38.65%
Book/sh	39.92	P/B	1.85	EPS next Y	26.20%	ROA	6.94%	Short Interest	0.83M	Perf Year	-2.03%
Cash/sh	9.48	P/C	7.79	EPS next 5Y	20.00%	ROE	8.29%	52W Range	49.24 - 94.57	Perf YTD	3.47%
Dividend Est.	-	P/FCF	29.42	EPS past 5Y	-13.18%	ROI	7.38%	52W High	-21.86%	Beta	1.00
Dividend TTM	-	Quick Ratio	12.72	Sales past 5Y	-3.89%	Gross Margin	67.06%	52W Low	50.08%	ATR (14)	2.42
Dividend Ex-Date	Jul 02, 2010	Current Ratio	14.15	EPS Y/Y TTM	253.69%	Oper. Margin	7.48%	RSI (14)	51.28	Volatility	2.72% 3.21%
Employees	58	Debt/Eq	0.01	Sales Y/Y TTM	-40.20%	Profit Margin	39.72%	Recom	1.20	Target Price	116.80
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	199.40%	Payout	0.00%	Rel Volume	0.79	Prev Close	72.32
Sales Surprise	9.58%	EPS Surprise	108.87%	Sales Q/Q	-44.22%	Earnings	May 07 AMC	Avg Volume	179.37K	Price	73.90
SMA20	-1.51%	SMA50	-0.91%	SMA200	10.33%	Trades		Volume	141,782	Change	2.18%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169
Sep-05-17	Resumed	H.C. Wainwright	Buy	$150
Oct-05-16	Reiterated	H.C. Wainwright	Buy	$146 → $160
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell	$104 → $110

Show Previous Ratings

Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Loading…
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
04:01PM	Loading…
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations (GlobeNewswire)
Dec-11-23 09:00AM	Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology (GlobeNewswire)
04:02PM	Loading…
Dec-06-23 04:02PM	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Business Wire)
Dec-01-23 08:20AM	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications (GlobeNewswire)
Nov-28-23 09:01AM	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-23 04:47PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:01PM	Ligand Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 09:00AM	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial (GlobeNewswire)
Nov-01-23 08:00AM	Ligand Acquires Royalty on Sanofis TZIELD for $20 Million (Business Wire)
Oct-25-23 04:01PM	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Business Wire)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire)
Oct-09-23 06:15PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-03-23 06:00PM	Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know (Zacks)
Oct-02-23 09:00AM	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms (GlobeNewswire)
Sep-27-23 09:00AM	Ligand Acquires Assets of Novan, Inc. for $12.2 Million (Business Wire)
Sep-26-23 05:05PM	Ligand Appoints Martine Zimmermann to its Board of Directors (Business Wire)
Sep-22-23 09:00AM	Ligands Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (Business Wire)
Sep-21-23 09:20AM	Ligands Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control (Business Wire)
Sep-18-23 05:17PM	Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio (Business Wire)
Sep-01-23 10:02PM	Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 04:01PM	Ligand Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-27-23 01:30PM	Ligands Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials (Business Wire)
Jul-25-23 04:30PM	Ligand To Report Second Quarter 2023 Financial Results On August 8 (Business Wire)
Jul-17-23 08:59AM	Ligand Offers $15 Million to Acquire Assets of Novan, Inc. (Business Wire)
08:45AM	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection (GlobeNewswire)
Jun-29-23 09:00AM	Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting (GlobeNewswire)
Jun-21-23 08:00PM	LGND: Lowering target price to $81.00 (Argus Research)
Jun-09-23 09:40AM	Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-06-23 11:40AM	LGND or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
11:10AM	UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health (Zacks)
Jun-05-23 11:49AM	Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat (Zacks) -5.72%
09:01AM	Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer (GlobeNewswire)
Jun-02-23 12:39PM	FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer (Zacks) +5.77%
12:35PM	Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study (Zacks)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-30-23 07:01PM	3 Stocks That Smart Investors Should Be Flocking to Now (InvestorPlace)
May-25-23 05:00PM	Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023 (GlobeNewswire)
May-24-23 09:55AM	Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet (Zacks)
09:40AM	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? (Zacks)
May-17-23 01:59PM	Viking (VKTX) Up 12% as VKTX-2809 Meets Goals in NASH Study (Zacks)
08:07AM	Zacks.com featured highlights include J.B. Hunt Transport Services, Archer-Daniels-Midland, NVIDIA, Tractor Supply and AmerisourceBergen (Zacks)
May-16-23 09:56AM	Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far (Zacks)
07:30AM	Ligands Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) (Business Wire)
07:00AM	Load Up on These 5 Exceptional Relative Price Strength Stocks (Zacks)
May-12-23 12:08PM	ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why (Zacks)
11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 12:32PM	Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings (Zacks)
09:55AM	Wall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to Trade (Zacks)
May-06-23 10:13AM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? (Simply Wall St.)
May-05-23 10:00AM	Best Momentum Stocks to Buy for May 5th (Zacks)
May-04-23 05:45PM	Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	Ligand Reports First Quarter 2023 Financial Results (Business Wire)
06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-02-23 08:30PM	2 Medical Stocks to Buy Before Earnings (Zacks)
12:06PM	Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y (Zacks)
11:40AM	LGND vs. REGN: Which Stock Is the Better Value Option? (Zacks)
Apr-28-23 02:04PM	Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
Apr-27-23 09:04AM	Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates (Zacks)
Apr-26-23 08:00PM	LGND: Lowering target price to $81.00 (Argus Research)
Apr-24-23 04:01PM	Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 (Business Wire)
Apr-20-23 09:55AM	Does Ligand (LGND) Have the Potential to Rally 41.24% as Wall Street Analysts Expect? (Zacks)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-18-23 12:56PM	Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data (Zacks)
Apr-17-23 01:13PM	Bristol Myers (BMY), TSVT Application for Abecma Accepted (Zacks)
09:40AM	Is Hologic (HOLX) Outperforming Other Medical Stocks This Year? (Zacks)
Apr-14-23 01:48PM	Merck's (MRK) Keytruda sBLA Accepted by FDA for Gastric Cancer (Zacks)
Apr-13-23 06:28AM	Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 41%? (Simply Wall St.)
Apr-07-23 06:40PM	Tillys, American Public Education Stock See Action From Activist Investors (Barrons.com)
Apr-06-23 10:23AM	Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio (Zacks)
Apr-04-23 12:02PM	Oncternal (ONCT) Down on Restructuring Plan to Extend Runway (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aryeh Jason	Director	Apr 30 '24	Option Exercise	52.30	2,406	125,834	76,828	May 02 06:07 PM
KOZARICH JOHN W	Director	Apr 24 '24	Option Exercise	39.35	2,893	113,840	42,523	Apr 26 06:35 PM
Davis Todd C	Chief Executive Officer	Mar 25 '24	Option Exercise	57.39	16,015	919,147	120,160	Mar 27 05:47 PM
Aryeh Jason	Director	Mar 05 '24	Option Exercise	39.35	2,893	113,840	74,422	Mar 06 05:28 PM
Sabba Stephen L	Director	Mar 05 '24	Option Exercise	0.00	2,893	0	30,819	Mar 07 01:27 PM
Sabba Stephen L	Director	Mar 05 '24	Sale	74.30	1,893	140,650	28,926	Mar 07 01:27 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Option Exercise	56.62	1,264	71,564	29,895	Feb 29 06:50 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Sale	88.46	140	12,384	29,755	Feb 29 06:50 PM
Davis Todd C	CHIEF EXECUTIVE OFFICER	Sep 22 '23	Buy	59.38	4,000	237,529	73,090	Sep 25 04:44 PM
KOZARICH JOHN W	Director	May 16 '23	Sale	77.20	4,444	343,081	38,488	May 18 05:18 PM
Sabba Stephen L	Director	May 10 '23	Option Exercise	0.00	6,408	0	32,192	May 12 03:43 PM
Sabba Stephen L	Director	May 10 '23	Sale	77.13	6,408	494,225	25,784	May 12 03:43 PM
KOZARICH JOHN W	Director	May 08 '23	Option Exercise	18.82	6,408	120,599	48,621	May 10 07:15 PM
KOZARICH JOHN W	Director	May 08 '23	Sale	76.56	6,408	490,628	42,213	May 10 07:15 PM

Open in Screener

VKTX

Viking Therapeutics Inc

May 03 • 04:00PM ET

76.97

Dollar change +1.21
Percentage change 1.60	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

VKTX Viking Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF VB IWO VBK SCHA VTWO VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.93	Insider Own	8.08%	Shs Outstand	110.27M	Perf Week	3.58%
Market Cap	8.49B	Forward P/E	-	EPS next Y	-1.54	Insider Trans	-8.73%	Shs Float	101.35M	Perf Month	4.47%
Income	-93.72M	PEG	-	EPS next Q	-0.27	Inst Own	68.88%	Short Float	11.00%	Perf Quarter	228.23%
Sales	0.00M	P/S	-	EPS this Y	-21.98%	Inst Trans	-0.29%	Short Ratio	1.71	Perf Half Y	704.28%
Book/sh	8.47	P/B	9.08	EPS next Y	-38.74%	ROA	-16.76%	Short Interest	11.15M	Perf Year	258.83%
Cash/sh	8.73	P/C	8.81	EPS next 5Y	40.00%	ROE	-17.55%	52W Range	8.28 - 99.41	Perf YTD	313.59%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.89%	ROI	-10.03%	52W High	-22.57%	Beta	1.12
Dividend TTM	-	Quick Ratio	29.48	Sales past 5Y	0.00%	Gross Margin	-	52W Low	829.59%	ATR (14)	4.83
Dividend Ex-Date	-	Current Ratio	29.48	EPS Y/Y TTM	0.82%	Oper. Margin	0.00%	RSI (14)	59.51	Volatility	6.11% 5.68%
Employees	27	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.09	Target Price	112.26
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-6.06%	Payout	-	Rel Volume	0.57	Prev Close	75.76
Sales Surprise	-	EPS Surprise	6.04%	Sales Q/Q	-	Earnings	Apr 24 AMC	Avg Volume	6.51M	Price	76.97
SMA20	9.18%	SMA50	7.69%	SMA200	157.16%	Trades		Volume	3,706,775	Change	1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-26-24	Reiterated	Oppenheimer	Outperform	$116 → $138
Mar-07-24	Initiated	Jefferies	Buy	$110
Feb-28-24	Reiterated	Oppenheimer	Outperform	$46 → $116
May-31-23	Resumed	ROTH MKM	Buy	$32
Mar-28-23	Reiterated	Maxim Group	Buy	$15 → $25
Mar-17-23	Initiated	Stifel	Buy	$22
Jul-29-21	Resumed	BTIG Research	Buy	$20
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$27 → $12
Jun-05-20	Initiated	BMO Capital Markets	Outperform	$14
May-05-20	Initiated	Chardan Capital Markets	Buy	$15
May-01-20	Initiated	BTIG Research	Buy	$9
Jul-16-19	Initiated	Oppenheimer	Outperform	$12
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform	$10 → $21
Mar-14-19	Reiterated	Maxim Group	Buy	$28 → $20
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy	$16
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	Raymond James	Outperform	$15 → $43
Sep-18-18	Reiterated	Maxim Group	Buy	$14 → $28

Show Previous Ratings

May-03-24 03:05AM	Viking Therapeutics Insider Sold Shares Worth $22,136,474, According to a Recent SEC Filing (MT Newswires)
May-01-24 11:59AM	Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge (InvestorPlace)
Apr-28-24 10:30AM	Is Viking Therapeutics Incredibly Undervalued? (Motley Fool)
09:07AM	Can This High-Flying Stock 10x in 10 Years? (Motley Fool)
Apr-26-24 08:15AM	Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript (Insider Monkey) +7.91%
06:00AM	Loading…
06:00AM	3 Biotech Stocks to Buy on the Dip: April 2024 (InvestorPlace)
Apr-25-24 11:28AM	11 Oversold MidCap Stocks To Buy Now (Insider Monkey) +5.82%
10:30AM	3 Millionaire-Maker Biotech Stocks (Motley Fool)
09:01AM	Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday (MT Newswires)
07:37AM	Q1 2024 Viking Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:20AM	Viking Therapeutics Inc (VKTX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ... (GuruFocus.com)
Apr-24-24 08:57PM	VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:37PM	Viking Therapeutics Reports First Quarter 2024 Results: Aligns with Analyst Projections (GuruFocus.com)
05:32PM	Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours (MT Newswires)
04:05PM	Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
05:50AM	Loading…
05:50AM	Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon. (Motley Fool)
Apr-23-24 09:15AM	Better Buy: Pfizer vs. Viking Therapeutics (Motley Fool)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Apr-19-24 05:45PM	Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
11:16AM	Viking (VKTX) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-17-24 04:05PM	Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 (PR Newswire)
Apr-16-24 01:19PM	These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? (InvestorPlace)
Apr-13-24 08:47AM	3 Magnificent Stocks That Could Double or More by 2030 (Motley Fool)
Apr-12-24 06:25AM	Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027 (InvestorPlace)
Apr-11-24 01:49PM	If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names (InvestorPlace)
12:24PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 (InvestorPlace)
Apr-10-24 05:45PM	Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know (Zacks)
08:59AM	What Makes Viking Therapeutics (VKTX) an Attractive Potential Opportunity? (Insider Monkey)
Apr-09-24 10:00AM	Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics (Motley Fool)
06:45AM	Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead. (Motley Fool)
05:55AM	Loading…
Apr-08-24 05:55AM	Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It. (Motley Fool)
Apr-06-24 08:47PM	10 Best Weight Loss Drug Stocks to Buy Now (Insider Monkey)
07:45AM	Is it Too Late to Buy Viking Therapeutics Stock? (Motley Fool)
Apr-05-24 07:15AM	Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics (Motley Fool)
Apr-04-24 09:15AM	Viking Therapeutics Just Announced More Positive Results: Time to Buy? (Motley Fool) -6.07%
06:30AM	1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now (Motley Fool)
05:50AM	2 Potentially Explosive Stocks to Buy in April (Motley Fool)
04:55AM	Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market? (Motley Fool)
Apr-02-24 05:50AM	Could Viking Therapeutics Stock Be a Millionaire Maker? (Motley Fool)
Apr-01-24 01:49PM	Viking Therapeutics Stock Has 72% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-31-24 10:15PM	20 Most Obese Countries in Asia (Insider Monkey)
09:31AM	Prediction: Pfizer Won't Acquire Viking Therapeutics. Here's Why. (Motley Fool)
06:15AM	5 Top Stocks to Buy in April (Motley Fool)
Mar-29-24 09:15AM	Is It Too Late to Buy Viking Therapeutics Stock? (Motley Fool)
09:00AM	Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
08:51AM	Why Viking Therapeutics Stock Was Rocketing Higher This Week (Motley Fool)
Mar-28-24 01:50PM	10 Best Growth Stocks To Invest In Now (Insider Monkey)
10:52AM	Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review (Investor's Business Daily)
05:50AM	5 Things You Need to Know If You Buy Viking Therapeutics Stock Today (Motley Fool)
Mar-27-24 12:42PM	Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data (Zacks)
12:22PM	IBD Stock Of The Day Eli Lilly Jumps Early Entry As Viking Charges Obesity Space (Investor's Business Daily)
Mar-26-24 04:15PM	Viking Surges After Weight-Loss Pill A Rival To Novo, Lilly Beats Expectations In Just 28 Days (Investor's Business Daily) +16.82%
01:25PM	Search continues after Baltimore bridge collapse, Trump Media stock jumps: Yahoo Finance Live (Yahoo Finance Video)
01:02PM	Viking Therapeutics Stock Rises After Data on Obesity Pill (Barrons.com)
12:59PM	Viking Therapeutics stock rises on positive Phase 1 weight-loss pill data (Yahoo Finance)
11:58AM	Ozempic maker Novo Nordisk gets more weight loss drug competition as a rival releases promising data (Quartz)
11:28AM	Why Viking Therapeutics Stock Is Skyrocketing Today (Motley Fool)
11:17AM	Viking Therapeutics stock surges on weight loss pill data (Yahoo Finance Video)
11:15AM	Viking Therapeutics Soars After Reporting Positive Results From Oral Weight-Loss Drug (Investopedia)
11:13AM	Viking Therapeutics Posts Promising Early Weight-Loss Data as Cost Worries Escalate (Barrons.com)
10:57AM	Why Is Viking Therapeutics (VKTX) Stock Up 24% Today? (InvestorPlace)
10:07AM	Viking Therapeutics: Buy, Sell, or Hold? (Motley Fool)
08:06AM	Viking stays in obesity drug race with early data for weight loss pill (BioPharma Dive)
07:12AM	Viking Therapeutics' weight-loss tablet shows promise in small study (Reuters)
07:09AM	Viking Therapeutics says its experimental tablet reduced weight in early-stage study (Reuters)
07:03AM	Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 (PR Newswire)
05:51AM	Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? (Motley Fool)
04:11AM	2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street (Motley Fool)
Mar-25-24 06:25AM	Novo Nordisk and Eli Lilly May Finally Have Some Real Competition (Motley Fool)
Mar-24-24 09:15AM	Is Viking Therapeutics Stock a Millionaire Maker? (Motley Fool)
Mar-23-24 05:53AM	Where Will Viking Therapeutics Stock Be in 10 Years? (Motley Fool)
Mar-22-24 04:55AM	Could Viking Therapeutics Become the Next Eli Lilly? (Motley Fool)
Mar-21-24 08:49AM	Viking Therapeutics Stock Has 55% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-20-24 08:30AM	2 Incredible Growth Stocks to Buy Right Now (Motley Fool) +8.99%
08:00AM	Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss (Investor's Business Daily)
Mar-19-24 09:45AM	Warning: This Skyrocketing Stock Has a Hidden Risk (Motley Fool)
Mar-17-24 09:15AM	Where Will Viking Therapeutics Be in 5 Years? (Motley Fool)
08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-16-24 08:17AM	Will Viking Therapeutics Get Acquired? (Motley Fool)
Mar-15-24 09:45AM	2 Stocks That Have More Than Tripled This Year: Are They Buys? (Motley Fool)
05:50AM	Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market? (Motley Fool)
Mar-14-24 09:38AM	12 Most Profitable Biotech Stocks To Invest In (Insider Monkey) -9.60%
Mar-13-24 07:35AM	Unleashing the Bulls: 3 Top Stocks to Charge Ahead in March (InvestorPlace) +7.24%
05:03AM	Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market? (Motley Fool)
Mar-11-24 06:53AM	Is Viking Therapeutics Stock a Buy? (Motley Fool) -11.62%
Mar-09-24 04:47PM	Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock. (Motley Fool)
Mar-08-24 01:03PM	3 Stock Winners That Are Up 1,000% or More in 2024 (InvestorPlace)
06:47AM	Viking (VKTX) Stock Down on Novo Nordisk's Obesity Pill Data (Zacks)
Mar-07-24 12:05PM	Why Viking Therapeutics Stock Is Plunging Today (Motley Fool) -18.84%
Mar-06-24 05:50AM	Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News? (Motley Fool)
Mar-05-24 11:16AM	A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried? (Motley Fool)
06:15AM	Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly (Motley Fool)
Mar-04-24 04:45PM	Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) +7.18%
05:58AM	1 Wall Street Analyst Thinks Viking Therapeutics Stock Is Going to $116. Is It a Buy Around $81? (Motley Fool)
Mar-03-24 09:35AM	Better Buy: Eli Lilly vs. Viking Therapeutics (Motley Fool)
07:41AM	Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now. (Motley Fool)
Mar-01-24 05:59PM	The Score: Dominos Pizza, Macys, Spirit AeroSystems and More Stocks That Defined the Week (The Wall Street Journal) +10.60%
12:11PM	Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review (Investor's Business Daily)
07:31AM	2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years (Motley Fool)
Feb-29-24 02:21PM	Viking Therapeutics stock has wild week after weight-loss drug results impress Wall Street (Yahoo Finance) -18.47%

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ZANTE GREG	Chief Financial Officer	May 03 '24	Option Exercise	4.86	34,249	166,285	241,610	May 03 08:51 PM
ZANTE GREG	Chief Financial Officer	May 03 '24	Sale	74.69	66,756	4,986,008	174,854	May 03 08:51 PM
Mancini Marianna	Chief Operating Officer	May 01 '24	Option Exercise	6.18	281,425	1,740,575	629,933	May 02 09:27 PM
Mancini Marianna	Chief Operating Officer	May 01 '24	Sale	78.66	281,425	22,136,474	348,508	May 02 09:27 PM
Lian Brian	President & CEO	Feb 09 '24	Sale	29.90	45,000	1,345,500	2,139,882	Feb 09 08:59 PM
Lian Brian	President & CEO	Feb 08 '24	Option Exercise	3.76	189,079	711,367	2,404,882	Feb 08 07:40 PM
Rouan Sarah Kathryn	Director	Feb 08 '24	Option Exercise	8.32	25,000	208,000	25,000	Feb 08 07:38 PM
Lian Brian	President & CEO	Feb 08 '24	Sale	26.87	269,079	7,230,784	2,184,882	Feb 08 07:40 PM
Rouan Sarah Kathryn	Director	Feb 08 '24	Sale	28.05	25,000	701,250	0	Feb 08 07:38 PM
Lian Brian	President & CEO	Jan 31 '24	Option Exercise	1.23	85,000	104,550	2,349,882	Jan 31 08:39 PM
Lian Brian	President & CEO	Jan 31 '24	Sale	24.71	85,000	2,100,750	2,264,882	Jan 31 08:39 PM
Lian Brian	President & CEO	Jan 30 '24	Option Exercise	1.23	35,000	43,050	2,299,882	Jan 30 09:05 PM
Lian Brian	President & CEO	Jan 30 '24	Sale	23.95	35,000	838,250	2,264,882	Jan 30 09:05 PM
Rouan Sarah Kathryn	Director	Jan 19 '24	Option Exercise	8.32	30,000	249,600	30,000	Jan 19 08:35 PM
Rouan Sarah Kathryn	Director	Jan 19 '24	Sale	23.05	30,000	691,500	0	Jan 19 08:35 PM
ZANTE GREG	Chief Financial Officer	Jan 04 '24	Sale	17.90	15,000	268,500	180,730	Jan 04 09:35 PM
Rowland Charles A Jr	Director	May 16 '23	Option Exercise	1.08	40,000	43,200	70,000	May 18 06:31 PM
MACARTNEY LAWSON	Director	May 16 '23	Option Exercise	1.19	16,000	19,040	63,965	May 18 06:30 PM
Rowland Charles A Jr	Director	May 16 '23	Sale	25.00	40,000	1,000,000	30,000	May 18 06:31 PM
MACARTNEY LAWSON	Director	May 16 '23	Sale	24.00	16,000	384,000	47,965	May 18 06:30 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

OABI

OmniAb Inc

LGND

Ligand Pharmaceuticals, Inc.

VKTX

Viking Therapeutics Inc

Upgrade your FINVIZ experience